The Latest Cardiac and Vascular News
Bagsværd, Denmark, 8 August 2023 – Novo Nordisk today announced the headline results from the SELECT cardiovascular outcomes trial. The double-blinded trial compared subcutaneous once-weekly semaglutide 2.4 mg with placebo as an adjunct to standard of care for prevention of major adverse cardiovascular events (MACEs) over a period of up to five years. […]
Copenhagen-based research center is awarded up to DKK 1 billion (€134.2 million) from the Novo Nordisk Foundation to support research toward innovative approaches to the diagnosis, prevention, and treatment of cardiometabolic diseases. COPENHAGEN, Denmark , April 25, 2023 /PRNewswire/ — The prevalence of cardiometabolic diseases such as diabetes, obesity and cardiovascular disease continues to increase […]
HS-001 consists of clusters of purified heart muscle cells derived from induced pluripotent stem cells (iPSCs). Clinical phase 1/2 study (LAPiS Study) will enrol 10 patients with advanced heart failure caused by ischaemic heart disease. Tokyo, Japan and Bagsværd, Denmark, 10 February 2023 – Heartseed Inc. (Heartseed) and Novo Nordisk A/S today announced that Heartseed has successfully dosed the first patient in […]
Financial report for the period 1 January 2021 to 30 September 2021 3 November 2021 Novo Nordisk’s net profit increased by 12% in the first nine months of 2021 Operating profit increased by 5% in Danish kroner and by 12% at constant exchange rates (CER). Sales increased by 8% in […]
Bagsværd, Denmark, 24 September 2020 – Novo Nordisk today announced the results of the CAPTURE study, a global non-interventional study to uncover the prevalence of cardiovascular disease and risk and its management in people living with type 2 diabetes. The study, the first of its kind and involving nearly 10,000 participants […]
New initiative will identify gaps in care, spur quality improvement in treating vulnerable patients WASHINGTON, Sept. 10, 2020 /PRNewswire/ — The American College of Cardiology, in partnership with Novo Nordisk Inc., is launching Transforming Cardiovascular Risk in Diabetes (TRANSFORM CVRiD), a new, two-year health care quality initiative to promote cardiovascular risk reduction and […]
